vs
Side-by-side financial comparison of AstroNova, Inc. (ALOT) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $39.2M, roughly 1.7× AstroNova, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 1.0%, a 38.4% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $3.3M).
AstroNova, Inc. is a global technology firm designing, manufacturing and distributing specialty data visualization products, including high-performance label printers, test and measurement equipment, and aerospace-grade data recording systems, serving aerospace, manufacturing, retail and healthcare markets worldwide.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
ALOT vs SLNO — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.2M | $66.0M |
| Net Profit | $378.0K | $26.0M |
| Gross Margin | 36.2% | 98.3% |
| Operating Margin | 3.3% | 33.5% |
| Net Margin | 1.0% | 39.4% |
| Revenue YoY | -3.4% | — |
| Net Profit YoY | 221.5% | 134.0% |
| EPS (diluted) | $0.05 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $39.2M | — | ||
| Q3 25 | $36.1M | $66.0M | ||
| Q2 25 | $37.7M | $32.7M | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $40.5M | — | ||
| Q2 24 | $33.0M | — | ||
| Q1 24 | $39.6M | — | ||
| Q4 23 | $37.5M | — |
| Q4 25 | $378.0K | — | ||
| Q3 25 | $-1.2M | $26.0M | ||
| Q2 25 | $-376.0K | $-4.7M | ||
| Q4 24 | $240.0K | — | ||
| Q3 24 | $-311.0K | — | ||
| Q2 24 | $1.2M | — | ||
| Q1 24 | $2.7M | — | ||
| Q4 23 | $2.8M | — |
| Q4 25 | 36.2% | — | ||
| Q3 25 | 32.2% | 98.3% | ||
| Q2 25 | 33.6% | 97.9% | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 35.3% | — | ||
| Q2 24 | 36.3% | — | ||
| Q1 24 | 31.9% | — | ||
| Q4 23 | 39.4% | — |
| Q4 25 | 3.3% | — | ||
| Q3 25 | -2.0% | 33.5% | ||
| Q2 25 | 1.5% | -20.0% | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 9.9% | — | ||
| Q4 23 | 12.3% | — |
| Q4 25 | 1.0% | — | ||
| Q3 25 | -3.4% | 39.4% | ||
| Q2 25 | -1.0% | -14.4% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | -0.8% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 6.8% | — | ||
| Q4 23 | 7.3% | — |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.16 | $0.47 | ||
| Q2 25 | $-0.05 | $-0.09 | ||
| Q4 24 | $0.03 | — | ||
| Q3 24 | $-0.04 | — | ||
| Q2 24 | $0.15 | — | ||
| Q1 24 | $0.37 | — | ||
| Q4 23 | $0.37 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $76.9M | $494.8M |
| Total Assets | $140.8M | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.6M | — | ||
| Q3 25 | $3.9M | $498.9M | ||
| Q2 25 | $5.4M | $286.8M | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $4.8M | — | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $4.5M | — | ||
| Q4 23 | $4.8M | — |
| Q4 25 | $76.9M | — | ||
| Q3 25 | $75.8M | $494.8M | ||
| Q2 25 | $76.6M | $240.1M | ||
| Q4 24 | $92.2M | — | ||
| Q3 24 | $91.8M | — | ||
| Q2 24 | $91.2M | — | ||
| Q1 24 | $90.3M | — | ||
| Q4 23 | $86.9M | — |
| Q4 25 | $140.8M | — | ||
| Q3 25 | $143.1M | $599.9M | ||
| Q2 25 | $150.3M | $332.3M | ||
| Q4 24 | $166.5M | — | ||
| Q3 24 | $169.0M | — | ||
| Q2 24 | $126.6M | — | ||
| Q1 24 | $133.3M | — | ||
| Q4 23 | $134.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.4M | $43.5M |
| Free Cash FlowOCF − Capex | $3.3M | $43.5M |
| FCF MarginFCF / Revenue | 8.5% | 65.8% |
| Capex IntensityCapex / Revenue | 0.2% | 0.0% |
| Cash ConversionOCF / Net Profit | 9.05× | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $2.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.4M | — | ||
| Q3 25 | $249.0K | $43.5M | ||
| Q2 25 | $4.4M | $-12.6M | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $162.0K | — | ||
| Q2 24 | $6.9M | — | ||
| Q1 24 | $6.5M | — | ||
| Q4 23 | $1.2M | — |
| Q4 25 | $3.3M | — | ||
| Q3 25 | $202.0K | $43.5M | ||
| Q2 25 | $4.3M | $-12.6M | ||
| Q4 24 | $-5.0M | — | ||
| Q3 24 | $-176.0K | — | ||
| Q2 24 | $6.4M | — | ||
| Q1 24 | $6.0M | — | ||
| Q4 23 | $399.0K | — |
| Q4 25 | 8.5% | — | ||
| Q3 25 | 0.6% | 65.8% | ||
| Q2 25 | 11.5% | -38.6% | ||
| Q4 24 | -12.4% | — | ||
| Q3 24 | -0.4% | — | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 15.3% | — | ||
| Q4 23 | 1.1% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.0% | — | ||
| Q4 23 | 2.1% | — |
| Q4 25 | 9.05× | — | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q4 24 | -19.76× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.85× | — | ||
| Q1 24 | 2.38× | — | ||
| Q4 23 | 0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALOT
| Public Utilities Inventory Supplies | $20.6M | 53% |
| Hardware Products | $12.7M | 32% |
| Service And Other | $5.9M | 15% |
SLNO
Segment breakdown not available.
